A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $12 to $30

Futu NewsDec 17 21:00 · Ratings

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireDec 17 05:05

Annexon Biosciences' ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential

TipRanksDec 17 03:25 · Ratings

Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

GlobeNewswireDec 16 20:30

Express News | Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)

BreakingsDec 16 20:30

Annexon Insider Buyers Pleased With US$571k Return On Investment

Simply Wall StDec 13 18:06